Clofibrate is a fibric acid derivative used in the therapy of hypertriglyceridemia and dyslipidemia. Clofibrate therapy is associated with mild and transient serum aminotransferase elevations and with rare instances of acute liver injury.
Clofibrate (kloe fye' brate) is a fibric acid derivative. The lipid lowering activity of clofibrate is probably mediated by its interactions with the peroxisome proliferator activated receptor alpha (PPARα), which regulates gene expression of enzymes involved in fatty acid oxidation. Clofibrate increases lipoprotein lipase levels which enhances clearance of triglyceride rich lipoproteins. Clofibrate was available for many years and frequently used in the therapy of hypertriglyceridemia (Fredrickson types IV and V hyperlipidemia) and hypercholesterolemia (Fredrickson types IIa and IIb). Use of clofibrate decreased with the availability of statins for therapy of hyperlipidemia and subsequently it was withdrawn from use in 2002. Clofibrate was available previously in generic forms and under the brand name of Atromid-S as capsules of 500 mg. The recommended dosage was 2 grams daily in divided doses. Common side effects of clofibrate include headache, muscle aches and gastrointestinal upset. Fibrates have multiple drug interactions requiring careful review and use.
Mild, transient serum aminotransferase elevations develop in a small proportion of patients receiving clofibrate, but values above 3 times normal occur in 2% or less. These abnormalities are usually asymptomatic and transient, resolving even with continuation of clofibrate. There have been rare reports of clinically apparent liver injury in patients on clofibrate. Onset of injury is usually after 2 to 3 months of treatment and the pattern of serum enzyme elevations can be either cholestatic or hepatocellular. Symptoms of immunoallergic hepatitis are rare as are autoantibodies. Chronic therapy with clofibrate has also been linked to an increased rate of gallstones, particularly among patients with chronic cholestatic liver disease (primary biliary cirrhosis).
Mechanism of Injury
The mechanism of hepatotoxicity of clofibrate is not known but may relate to formation of toxic intermediates or interference with normal hepatic enzyme function. The development of gallstones during clofibrate therapy may relate to its effects in increasing cholesterol while lowering bile acid secretion in bile, thus favoring cholesterol supersaturation.
Outcome and Management
There have been no reports of acute liver failure, chronic hepatitis, cirrhosis or vanishing bile duct syndrome related to clofibrate therapy. There is likely to be some degree of cross reactivity to hepatotoxic reactions to fibrates, but not to statins.
REPRESENTATIVE TRADE NAMES
Clofibrate – Atromid-S®
FDA product labeling at DailyMed, National Library of Medicine, NIH
||CAS REGISTRY NUMBER
References updated: 15 May 2014
Zimmerman HJ. Drugs used in the treatment of hypercholesterolemia and hyperlipidemia. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 660-2. (Expert review of hepatotoxicity of lipid lowering agents including clofibrate, fenofibrate and gemfibrozil, all three of which can lead to mild-to-moderate serum aminotransferase elevations, and which have been associated with hepatic injury).
De Marzio DH, Navarro VJ. Fibrates. Hepatotoxicity of cardiovascular and
antidiabetic drugs: fibrates. In, Kaplowitz N, DeLeve LD, eds. Drug-induced
liver disease. 3rd ed. Amsterdam: Elsevier, 2013, pp. 527. (Review of
hepatotoxicity of fibrates; fenofibrate is the most commonly implicated fibrate
in causing liver injury, which can be severe and prolonged with autoimmune
features and the potential for chronicity).
Bersot TP. Drug therapy for hypercholesterolemia and dyslipidemia. In, Brunton
LL, Chabner BA, Knollman BC, eds. Goodman & Gilman’s the pharmacological
basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011, pp. 877-908.
(Textbook of pharmacology and therapeutics).
Smith AL, Macfie WG, Oliver MF. Clofibrate, serum enzymes and muscle pain. Br Med J 1970; 2: 86-8. PubMed Citation (Cross sectional study of 101 patients on clofibrate, 110 untreated and 85 controls, found no difference in mean AST levels, 2 patients had raised AST during follow up [117 and 140 U/L] not further characterized, but without accompanying CPK elevations).
Vester JW, Sunder JH, Aarons JH, Danowski TS. Long-term monitoring during clofibrate therapy. Clin Pharmacol Ther 1970; 11: 689-97. PubMed Citation (Analysis of 22 patients given clofibrate for 2-5 years, no changes in serum enzymes; one patient had rise in BSP clearance without other abnormalities).
Summerfield JA, Elias E, Sherlock S. Effects of clofibrate in primary biliary cirrhosis: hypercholesterolemia and gallstones. Gastroenterology 1975; 69: 998-1000. PubMed Citation (52 year old woman with primary biliary cirrhosis developed worsening cholestasis and multiple intra- and extra-hepatic gallstones 2 months after starting clofibrate, with resolution of stones with stopping therapy).
Jacobs WH. Intrahepatic cholestasis following the use of Atromid-S. Am J Gastroenterol 1976; 66: 69-71. PubMed Citation (70 year old woman developed jaundice 2 years after starting clofibrate [bilirubin 10.5 mg/dL, ALT 45 U/L, Alk P 125 U/L], biopsy showing intrahepatic cholestasis, degree of recovery not given).
Bateson MC, Maclean D, Ross PE, Bouchier IAD. Clofibrate therapy and gallstone induction. Am J Dig Dis 1978; 23: 623-8. PubMed Citation (Among patients with hyperlipidemia, 9 of 19 on clofibrate compared to 15 of 112 untreated patients had gallstones by oral cholecystograms; biliary cholesterol was higher in clofibrate treated group, saturation index 1.46 vs 1.03 ).
Schwandt P, Klinge O, Immich H. Clofibrate and the liver. Lancet 1978; 2: 325. PubMed Citation (40 patients had liver biopsy before and 3 month after starting clofibrate; slight decrease in hepatic fat, but no evidence of liver injury found).
Pierce EH, Chesler DL. Possible association of granulomatous hepatitis with clofibrate therapy. N Engl J Med 1978; 299: 314. PubMed Citation (69 year old woman developed jaundice 3 months after starting clofibrate [bilirubin 7.3 mg/dL, ALT 149 U/L, Alk P 454 U/L], biopsy showing intrahepatic cholestasis and granulomas, resolution 1 month after stopping).
Migneco G, Mascarella A, La Ferla A, Attianese R. [Clofibrate hepatitis. A case report] Minerva Med 1986; 77: 799-800. PubMed Citation (51 year old developed abdominal pain and fatigue 3 months after starting clofibrate [bilirubin normal, ALT 210 U/L] and rapid resolution on stopping; 4 months later she presented again having taken fenofibrate for 1 month [ALT 76 U/L, Alk P normal], and rapid resolution again on stopping).
Athyros VG, Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, Didangelos TP, Carina MV, Kranitsas DF, et al. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. Am J Cardiol 1997; 80: 608-13. PubMed Citation (389 patients treated with statin and fibrate combination for average of 2.5 years; 1.3% stopped because of ALT >3 times normal, all resolving within 4 weeks; no hepatitis or jaundice reported).
Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J; Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135: 1924-34. PubMed Citation (Among 300 cases of drug induced liver disease in the US collected from 2004 to 2008, 1 case was attributed to fenofibrate, but none to clofibrate or gemfibrozil).
OTHER REFERENCE LINKS
Top of page